Compare Salesforce Inc (CRM) vs DexCom, Inc. (DXCM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Salesforce Inc vs DexCom, Inc. — how do they compare? Salesforce Inc trades at $192.13 (market cap $161.73B), while DexCom, Inc. trades at $90.55 (market cap $33.79B). The key difference: Salesforce Inc is far larger — about 4.8× DexCom, Inc.'s market cap, and Salesforce Inc pays a 0.89% dividend while DexCom, Inc. pays none. Which is the better fit depends on your goals.
| CRM | DXCM | |
|---|---|---|
Market Cap | $161.73B | $33.79B |
Sector | Technology | Health |
52-Week High | $266.23 | $89.53 |
52-Week Low | $150.12 | $54.84 |
Enterprise Value | $191.77B | $33.24B |
Dividend Yield | 0.89% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Salesforce (CRM) trades at $192.28, down 2.65% today amid a broader tech sell-off, but maintains strong fundamentals with consistent earnings beats, robust profitability margins, and solid cash flow growth. The stock exhibits a bullish technical trend with key support at $193, while analyst consensus remains overwhelmingly positive with a $230.83 price target. Recent news highlights AI-driven growth potential but also sector-wide volatility concerns.
Outlook is favorable given CRM's rule of 44 performance, AI monetization momentum, and discounted valuation, though risks include competitive pressures, macroeconomic headwinds, and elevated RSI levels suggesting near-term overbought conditions. The company's double-digit revenue growth and expanding margins support long-term upside if execution continues.
DXCM trades at $90.23, up 2.94% today and near its 52-week high, with a bullish technical signal from moving averages. The company reported strong Q2 2026 earnings, beating EPS estimates with $0.70 versus $0.61 expected, and raised full-year guidance. Revenue growth remains robust at 13% year-over-year, supported by G7 system adoption and international expansion. Profit margins improved, with net income margin reaching 20.12% in 2025. Analyst sentiment is overwhelmingly positive, with 80% buy ratings.
The outlook for DXCM is favorable due to sustained demand for continuous glucose monitors and strategic initiatives like 'Road to 100'. Key risks include competitive pressures, regulatory scrutiny, and valuation multiples above industry averages. The stock's current price is slightly above the consensus target of $88.65, suggesting near-term consolidation may occur before further upside.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Salesforce Inc
Salesforce Inc provides enterprise cloud computing solutions. The company offers customer relationship management technology that brings companies and customers together. Its Customer 360 platform helps the group to deliver a single source of truth, connecting customer data across systems, apps, and devices to help companies sell, service, market, and conduct commerce. It also offers Service Cloud for customer support, Marketing Cloud for digital marketing campaigns, Commerce Cloud as an e-commerce engine, the Salesforce Platform, which allows enterprises to build applications, and other solutions, such as MuleSoft for data integration.
Read more on CRM →About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →
